Geoffrey Kunz, MD
Interventional Cardiology · Albuquerque, NMNPI 1306839071
Payments from drug & device makers
Across 683 payments — averaging $50.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$14K
- Edwards Lifesciences$7K
- Abiomed$5K
- Abbott$2K
- Medtronic$990
- Boston Scientific$852
- plus $5K from 24 others
Across 4 payments — averaging $68.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$276
What the payments were for
- Travel & lodging$4,95323%
- Food & beverage$16,97077%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 47 | $13,543 |
| Edwards Lifesciences | 76 | $6,853 |
| Abiomed | 85 | $4,796 |
| Abbott | 117 | $2,188 |
| Medtronic(2 entities) | 38 | $990 |
| Boston Scientific | 49 | $852 |
| Shockwave Medical, Inc | 48 | $772 |
| Philips North America LLC | 46 | $702 |
| Amgen | 38 | $658 |
| Ancora Heart, Inc. | 5 | $447 |
| W. L. Gore & Associates, Inc. | 14 | $359 |
| E.r. Squibb & Sons, L.L.C. | 18 | $328 |
| Novartis | 18 | $328 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $287 |
| Biosense Webster, Inc. | 9 | $228 |
| Cordis US CORP. | 8 | $204 |
| AstraZeneca | 12 | $177 |
| Livanova USA, Inc. | 3 | $162 |
| Johnson & Johnson | 8 | $153 |
| Bayer | 3 | $138 |
| Baxter Healthcare | 3 | $121 |
| Bolton Medical Inc | 1 | $111 |
| Pfizer | 5 | $85 |
| Inspire Medical Systems, Inc. | 2 | $73 |
| Teleflex LLC | 2 | $54 |
| Chiesi USA, Inc. | 2 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Terumo Medical Corporation | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Cook Medical LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$2,326
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,233
- PASCAL$844
- AccuCinch$418
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$376
- SAPIEN 3 Ultra RESILIA$372
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$260
- Mitra Clip system$243
- AVEIR$183
- EVOQUE$145
- COREVALVE EVOLUT R$141
- LifeSPARC$132
- COROFLOW$129
- Xience Sierra Coronary Stent$120
- Kerendia$117
- Grafts$111
- PRESSUREWIRE$101
How this compares
$34,706 in reported general payments places this provider in the 80th percentile of 25 interventional cardiology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 358 | $348,500 |
| UptraviSelexipag | 12 | $283,034 |
| OpsumitMacitentan | 13 | $169,515 |
| Repatha SureclickEvolocumab | 104 | $69,684 |
| EntrestoSacubitril/Valsartan | 50 | $47,663 |
| Tadalafil | 11 | $31,188 |
| XareltoRivaroxaban | 22 | $22,799 |
| JardianceEmpagliflozin | 12 | $11,566 |
| Ambrisentan | 13 | $9,710 |
| Metoprolol Succinate | 427 | $6,750 |
| Atorvastatin Calcium | 440 | $6,404 |
| Rosuvastatin Calcium | 265 | $3,825 |
| Losartan Potassium | 256 | $3,096 |
| ClopidogrelClopidogrel Bisulfate | 217 | $2,811 |
| Carvedilol | 274 | $2,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $20 | $452,55025 claims |
| PfizerEliquis | $85 | $348,500358 claims |
| NovartisEntresto | $328 | $47,66350 claims |
| Johnson & JohnsonXarelto | $153 | $22,79922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 25 interventional cardiology providers in New Mexico.
Other interventional cardiology in Albuquerque
- James BlankenshipAlbuquerque$782K
- Mark BieniarzAlbuquerque$299K
- Raymond YauAlbuquerque$215K
- Robert FedericiAlbuquerque$77K
- Sharif HalimAlbuquerque$34K
- Charles KimAlbuquerque$20K
- Harvey WhiteAlbuquerque$3K
- Guilherme MarinAlbuquerque$3K
- John BattyAlbuquerque$82
- Abdul KhanLas Cruces$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.